+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Proton Pump Inhibitors (PPIs) Market by Product and Geography - Global Forecast and Analysis 2019-2023 - Product Image

Proton Pump Inhibitors (PPIs) Market by Product and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4792973
  • Report
  • June 2019
  • Region: Global
  • 127 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Pfizer Inc.
  • MORE
Global Proton Pump Inhibitors (PPIs) Market: About this market

Proton pump inhibitors (PPIs) are drugs whose main mechanism is to inhibit the secretion of acid by the stomach, thus helping in reducing the symptoms of various acid-related diseases. This proton pump inhibitors (PPIs) market analysis considers sales from Over-the-counter (OTC) PPIs and prescription PPIs. Our analysis also considers the sales of proton pump inhibitors (PPIs) in Asia, Europe, North America, and ROW. In 2018, the OTC PPIs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as easy accessibility and affordability of OTC drugs will play a significant role in the OTC PPIs segment to maintain its market position. Also, our global proton pump inhibitors (PPIs) market report looks at factors such as reformulation of drugs and growth in prescription rates. However, the increasing lawsuits against PPIs, launch of generic PPIs, and stringent regulatory guidelines may hamper the growth of the proton pump inhibitors (PPIs) industry over the forecast period.

Global Proton Pump Inhibitors (PPIs) market: Overview

Reformulation of drugs

Vendors are trying to maintain their positions in the market by delaying the entry of generic versions and obtaining patent extensions through reformulation of drugs. This ensures the bioavailability of drugs and boosts patient compliance. The reformulation of already marketed drugs by vendors will lead to the expansion of the global proton pump inhibitors (PPIs) market at a CAGR of over 4% during the forecast period.

Rising prevalence of obesity

With the prevalence of obesity in older adults and children and adolescents, the risks to develop chronic diseases such as type 2 diabetes, cardiovascular diseases, and certain types of cancer is also increasing. This is driving the need for PPIs for the treatment of these diseases, which is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global proton pump inhibitors (PPIs) market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading proton pump inhibitors (PPIs) manufacturers, that include AstraZeneca Plc, Bayer AG, Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the proton pump inhibitors (PPIs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • OTC PPIs - Market size and forecast 2018-2023
  • Prescription PPIs - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Growing geriatric population
  • Rising prevalence of obesity
  • Rising utilization of PPIs
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bayer AG
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: OTC PPIs - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: OTC PPIs - Year-over-year growth 2019-2023 (%)
Exhibit 21: Prescription PPIs - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Prescription PPIs - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in North America
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in Europe
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Asia
Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in ROW
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Use of PPIs in different patient settings in 2010
Exhibit 42: Sales of Takeda’s PPIs after the launch of generics ($ millions)
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AstraZeneca Plc - Vendor overview
Exhibit 50: AstraZeneca Plc - Product segments
Exhibit 51: AstraZeneca Plc - Organizational developments
Exhibit 52: AstraZeneca Plc - Geographic focus
Exhibit 53: AstraZeneca Plc - Key offerings
Exhibit 54: AstraZeneca Plc - Key customers
Exhibit 55: Bayer AG - Vendor overview
Exhibit 56: Bayer AG - Product segments
Exhibit 57: Bayer AG - Organizational developments
Exhibit 58: Bayer AG - Geographic focus
Exhibit 59: Bayer AG - Segment focus
Exhibit 60: Bayer AG - Key offerings
Exhibit 61: Bayer AG - Key customers
Exhibit 62: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 63: Johnson & Johnson Services Inc. - Business segments
Exhibit 64: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 65: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 66: Johnson & Johnson Services Inc. - Segment focus
Exhibit 67: Johnson & Johnson Services Inc. - Key offerings
Exhibit 68: Johnson & Johnson Services Inc. - Key customers
Exhibit 69: Pfizer Inc. - Vendor overview
Exhibit 70: Pfizer Inc. - Business segments
Exhibit 71: Pfizer Inc. - Organizational developments
Exhibit 72: Pfizer Inc. - Geographic focus
Exhibit 73: Pfizer Inc. - Segment focus
Exhibit 74: Pfizer Inc. - Key offerings
Exhibit 75: Pfizer Inc. - Key customers
Exhibit 76: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 77: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 78: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 82: Validation techniques employed for market sizing
Exhibit 83: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global proton pump inhibitors (PPIs) market: AstraZeneca Plc, Bayer AG, Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rising prevalence of obesity”.

According to the report, one of the major drivers for this market is the reformulation of drugs.

Further, the report states that one of the major factors hindering the growth of this market is the increasing lawsuits against PPIs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca Plc
  • Bayer AG
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll